|Description||Fosdevirine is a highly potent next-generation Anti-HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 11 nM. It is a novel and once-daily (QD) inhibitor with activity against efavirenz-resistant strains. It demonstrated potent antiviral activity in treatment-naive HIV-infected subjects, and had favorable PK and resistance profiles. It was originally developed by idenix pharmaceuticals and was in clinical phase 2, but now it has been terminated.|
|Solubility||10 mM in DMSO|
|Application||Fosdevirine has potent antiviral activity.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Boiling Point||686.4±65.0 °C | Condition: Press: 760 Torr|
|Density||1.42±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Fosdevirine was originally developed by idenix pharmaceuticals and was in clinical phase 2, but now it has been terminated.|
Fosdevirine is a highly potent next-generation Anti-HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) with an EC50 of 11 nM. It is a novel and once-dail...
CP-94707 is a new nonnucleoside reverse transcriptase inhibitor (NNRTI).
The labeled form of Etravirine, is an inhibitor of HIV reverse transcriptase, could be used in the treatment of HIV infection.
Rilpivirine, also known as TMC278, is a drug used as part of antiretroviral therapy (ART). Rilpivirine is a second-generation non-nucleoside reverse transcripta...
IDX899 is a novel next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) with activity against efavirenz-resistant strains. It is used in the tre...